Ovarian Cancer

Let's start with the description of the case:

M.C.R. is a 63-year-old patient, diagnosed with operated ovarian cancer, metastatic. She came to us at the end of 2014, stage IV, with metastasis to liver and peritoneal carcinomatosis, with a prognosis of 12 months to live, and with physical discomfort that made her daily life considerably difficult.

We received M.C.R.'s medical documentation, in which we observed that it was a stage IV ovarian carcinoma, with metastasis to the liver, peritoneal carcinomatosis defined by the presence of diffuse thickening of the peritoneal adipose tissue and retroperitoneal and iliac lymph node involvement, in addition to presenting abundant ascites, which is frequent in cases of peritoneal carcinomatosis. He was receiving palliative chemotherapy.

In terms of symptoms, he presented with abdominal pain, vomiting, diarrhea, and difficulty feeding and sleeping. Many of these symptoms were related to the administration of chemotherapy.

Once the case was analyzed by our specialists, we informed the patient about what to expect with Escozul™ and the possibilities of achieving good results.

Each dose of Escozul™ is personalized, specific to the type of tumor and its aggressiveness. These doses can change over time according to the results observed in the patient. This requires an effective communication between the patient and our medical team to allow us to make the appropriate recommendations on different aspects. If the patient or family members do not maintain fluid communication with us, then the results with Escozul™ will not be as expected.

M.C.R. started treatment with Escozul™ at the beginning of December 2014.

Results and evolution:

From the beginning of the administration of Escozul™, M.C.R. could notice how it helped her to palliate the side effects of chemotherapy, which began to last less time than before starting with Escozul™, contributing to a faster recovery from the process.

M.C.R. continued with the treatment continuously and with increasing doses, under the advice of our specialists.

In May 2015 new tomography shows the hepatic lesions as calcified cysts of chronic infectious origin without contrast medium uptake and without presence of free abdominal fluid. The conclusion of the examination is that there were no visible tumor lesions in the body. At that time and by personal decision M.C.R. stopped treatment with Escozul™ for a few months, despite our recommendations to continue it for at least 6 months after the first cancer-free examination.

By September 2015, new CT scan showed again active liver lesions, with tumor lymph node growth again in retroperitoneum, signs of peritoneal carcinomatosis and abdomino-pelvic free fluid (ascites). The case was reevaluated and we started again treatment with higher doses seeking to counteract this new disease progression.

In CT In February 2016, the disease remained stable with respect to the last examination. We continued with dose increases seeking to improve M.C.R.'s condition and trying to reach again a regression of the disease.

In the last CT scan in January 2017, again the disease has been brought under control. The liver lesions show as calcified nodules without tumor activity, no ascites, no peritoneal involvement, no nodal growths. The examination shows no tumor lesions.

At this moment we continue the treatment with increasing doses, trying to maintain these results and avoid a new progression of the disease.

M.C.R. has managed to overcome his initial prognosis of life in more than 2 years and is currently free of tumor lesions. We always insist to our patients that consistency in the treatment with Escozul™ is vital to obtain good results. Even when the cancer disappears, Escozul™ should be continued for at least 6 months to prevent further progression of the disease.

As we always say, it is important to point out that it is not possible to generalize any results with Escozul™ to avoid creating false expectations in people, Escozul™ does not work miracles. Only working together and constant communication allow to keep the doses of Escozul™ personalized and functional against tumors.

It is also important to say that all the medical information of the case is available for consultation, as well as the contact with the medical counterpart of both the oncologist who attended the case and our specialists. We believe in transparency in dealing with our patients and the right to form an opinion based on information and analysis.

If you wish to be treated under the Escozul™ Protocol, you should know the following: Escozul™ is a product that we are still investigating, including its other properties such as analgesic and anti-inflammatory, therefore it is not a commercial product, that is, it cannot be sold. Each case that wishes to enter our protocol must be evaluated and approved because Escozul™ is not effective in all types of tumors. Once approved, the patient and his family members must commit to maintain a fluid contact with our medical team.

To enter the protocol you must send us an email to: servicios@lifescozulcuba.com indicating the patient's age, the type of cancer and the patient's physical and emotional state. This is the first step, and a specialist will take charge of the case. Our response time is an hour or two because each case is answered personally, not automatically. The idea is that the communication we establish is always governed by a professional and humane treatment.

Prepared by LifEscozul™ Group March/2017

Medical Documents

Let's start with the description of the case:

In September 2015 we were contacted by the patient's daughter as her breast had been discovered, at the end of August, an ovarian cancer, during a surgical intervention for a picture of acute abdominal pain. Prior to the operation, there were no symptoms indicating the presence of cancer. Unfortunately, ovarian cancer is a silent and difficult to detect type of cancer, which when it presents symptoms means that it is in an advanced stage.

On reviewing the documentation we found that it was a right ovarian cancer (papillary serous cystoadenocarcinoma), with tumor nodules in the peritoneum. The CA125 tumor antigen value was very high, at 983 when normal is up to 35. This is the tumor marker used to monitor tumor activity in ovarian cancer. She also presented bilateral pleural effusion (fluid in the lungs) and ascites (free abdominal fluid). Also, during surgery, a tumor mass in the colon had been removed.

At that time, the symptomatology of our patient, Teresita, was described as: mild abdominal pain, loss of appetite, being fed in small portions, sleep interrupted by abdominal discomfort, weight loss.

She was started on Escozul™ treatment in early October 2015. Our initial proposal was based on Teresita regaining quality of life. For us it was important that these symptoms did not translate into a depression that would put a stop to the comprehensive work on her.

Based on previous experiences, we proposed a dose for advanced disease with the objective of not only helping the patient to recover physically, but also to attack the disease in the strongest possible way, seeking to maximize the antitumor effect of Escozul™.

When starting Escozul™, the patient was receiving chemotherapy.

It is important to say that Escozul™ is a natural product that has been shown to eliminate tumor cells, without this meaning that it is a cure for cancer. Its capacity to inhibit malignant cell growth allows it to be used as a disease controller and the focus of the work is done so that the patient can live with his disease with the least possible effect on his daily routine.

Evolution, follow-up and current results:

In the case of ovarian cancer, follow-up is done through the value of the tumor marker CA125, since its decrease is an indicator of the effectiveness of the treatment on the tumor, this is why we periodically request the value of the antigen as a way to monitor the effect of Escozul™.

On October 30 we received results from the patient after the first month with Escozul™. The CA125 antigen value had dropped to 259. By December the marker value had decreased to 91.9. In less than three months the antigen value was reduced by more than 90%.

In December a CT scan was performed, showing a decrease in pleural effusion and no evidence of disease progression.

The patient's daughter reports that she has gained weight and remains in good physical condition.

In February 2016, the CA125 marker value dropped to 46.4, very close to normal (35). In the CT report on February 4, no presence of disease was noted and the abdominal free fluid had disappeared. Teresita is currently scheduled for surgery in March. She has been maintained with progressive doses of Escozul™ always seeking to improve the results obtained.

As we always say, it is important to point out that it is not possible to generalize any result with Escozul™ to avoid creating false expectations in people, Escozul™ does not work miracles. Only by working together and constant communication it is possible to keep the doses of Escozul™ personalized and functional against tumors.

It is also important to say that all the medical information of the case is available for consultation, as well as the contact with the medical counterpart of both the oncologist who attended the case and our specialists. We believe in transparency in dealing with our patients and the right to form an opinion based on information and analysis.

If you wish to be treated by our specialists please contact us at: servicios@lifescozulcuba.com . If you wish to learn more about Escozul™ and our work, please visit our website: www.escozul-cuba.com.

Prepared by LifEscozul™ Group

Medical Documents

Initial Diagnosis:

Our team received the medical documents of the case and the family's supplemental report on Cristina's physical condition. The analysis of the documentation showed that the patient had a primary ovarian cancer, specifically a bilateral mixed waxy cystoadenocarcinoma, which had been operated on. However, the CT scan showed liver metastases, possible tumor infiltration to the left anterolateral wall of the bladder and cervical uterine wall, as well as peritoneal lymph node involvement. The tumor marker for ovarian cancer, CA125, was at a value of 67.20 (normal value up to 35).

Symptoms:

In terms of symptoms Cristina presented with loss of appetite, loss of body weight, interrupted rest.

Analysis of the case and treatment with Escozul™:

With these results we explained to the family Cristina's situation, which was not one of the most encouraging due to the extensive metastatic involvement, also telling them about the possible response to be obtained with the use of Escozul™. A high dose was prescribed, to be increased progressively, looking for a positive response as far as possible according to the conditions of the case.

Cristina started treatment with Escozul™ in April 2014, she was pending to start chemotherapy.

Evolution and current results:

We received Cristina's first report in May 2014, despite having started chemotherapy shortly after starting Escozul™ treatment, she was feeling well, with minimal discomfort. The tumor marker CA125 had dropped to 27.50, already within the normal range.

By June, Cristina continued to be in good physical condition, with very mild adverse reactions to the chemo, such as rash. The antigen had dropped again to 19.1. This month's CT scan showed no tumor lymph node or nearby organ involvement.

With these results, the patient could be operated again in August 2014, to remove uterus and pelvic nodes. No tumor cells were found in any of the organs removed.

By November 2014, the antigen had dropped again to 12.7.

In January 2015, we received new report and Cristina remained in good physical condition. The CA125 was at 11.1.

In March 2015 report Cristina was doing very well, had regained weight and her appearance was normal. She had finished chemotherapy in January.

In April a new CT scan was performed which showed only some liver lesions, although blood tests were normal. Physically she was in very good condition. We continued the treatment with Escozul™, with progressive doses.

Cristina continued to improve physically and in tomography performed in January 2016, no tumor lesion was found, the liver only showed simple cysts.

Cristina continued treatment with Escozul™ until completing her second year of treatment in April 2016, with an increasing dosage schedule to prevent recurrence of the disease.

Cristina is currently cancer-free, having only periodic check-ups.

Despite her advanced diagnosis, the use of Escozul™ along with chemotherapy, has allowed Cristina to beat the disease, with minimal adverse effects from the chemo and she has been able to regain her life expectancy.

Summary:

As we always say, it is important to point out that it is not possible to generalize any results with Escozul™ to avoid creating false expectations in people, Escozul™ does not work miracles. Only working together and constant communication allow us to keep the doses of Escozul™ personalized and functional against tumors.

It is also important to say that all the medical information of the case is available for consultation, as well as the contact with the medical counterpart of both the oncologist who attended the case and our specialists. We believe in transparency in dealing with our patients and the right to form an opinion based on information and analysis.

If you wish to be treated under the Escozul™ Protocol, please fill out the form on our website: www.escozul-cuba.com and one of our specialists will be at your disposal.

Medical Documents

Initial Diagnosis:

History of ovarian cancer 5 years ago operated on, at the time of evaluation she had ovarian cancer metastasis to pleura, liver, spleen, peritoneum, with presence of metastases to the pleura, liver, spleen, peritoneum, with presence of metastases to the peritoneum.

peritoneum, with presence of ascites (fluid accumulation in abdomen) and right pleural effusion.

Symptoms:

• - Right-sided abdominal pain, with swelling due to fluid accumulation.
• - Loss of appetite
• - Very sleepy
• - Pallor and lack of energy.

Treatments:

Started Escozul™ in February 2015. Started palliative chemotherapy one week before starting Escozul™.

It is important to remember that Escozul™ is a natural product that has the ability to eliminate tumor cells, without meaning that it is a cure for cancer. Its ability to inhibit malignant cell growth allows it to be used as a disease controller and the focus of work is done looking for the patient to be able to live with his disease with the least possible affectation to his daily routine.

Evolution and current results:

At the time of starting treatment the CA125 antigen, which is used to monitor carcinogenic activity in ovarian cancer, had a value of 1635.80

(normal value up to 35).

The family indicated that in the application of the second chemotherapy, which was already consuming Escozul™, the recovery was better with fewer side effects, and that the patient felt better, less tired and with more spirit and energy.

One month after starting treatment the CA125 value had decreased to 661, by more than half.

In the third cycle of chemotherapy the adverse effects further decreased and recovery lasted fewer days.

By the end of March the family indicates that the patient has a better countenance, her appetite improved normalizing and the abdominal swelling had decreased considerably.

In examinations in July 2015, 5 months after starting Escozul™ treatment, in conjunction with chemotherapies, the CT scan of the chest, abdomen and pelvis, showed that there was no presence of metastases anywhere in the body. The CA125 ovarian cancer antigen is within normal limits with a value of 23.4.

In this case, not only has it been possible to improve the patient's quality of life, allowing her to lead a normal life, but Escozul™ has also helped her to go through the chemotherapy process with fewer side effects and less recovery time, in addition to eliminating the secondary lesions and cancerous activity in the body in 5 months.

Currently, he continues to take Escozul™ with progressive doses in order to maintain these results.

It is important to point out that it is not possible to generalize any result with Escozul™ in order to avoid creating false expectations in people. Each case we receive is analyzed in order to inform the family what to expect. Each person is a completely different universe, even if they have the same disease. This document is not a testimony but a summary of evolution where medical information is available for consultation.

Medical Documents

Case Summary:

Isabel was diagnosed in 2009 with stage IIIC ovarian cancer, she started treatment with chemotherapy and later with Escozul™, achieving total regression of the disease.

By February 2012, as the disease had disappeared, the patient decided to discontinue treatment and keep control check-ups.

However, in July 2012 she began to present abdominal pains, so she underwent a CT scan which showed a large tumor mass in the upper hemiabdomen

and tumor implants at the level of the hepatic hilum and in the right lobe of the liver, with pulmonary involvement.

She contacted us again:

Faced with this situation, Isabel returned to treatment with radiotherapy and chemotherapy, but only with a partial response of the disease, in addition to the fact that she presented toxicity from the chemo, so, in early 2013, she contacted us again to resume treatment with Escozul™.

It is important to remember that Escozul™ is a natural product that has the ability to eliminate tumor cells, without this meaning that it is a cure for cancer. Its ability to inhibit malignant cell growth allows it to be used as a disease controller and the focus of work is done seeking that the patient can live with his disease with the least possible affectation to his daily routine.

Evolution and current results:

Treatment with Escozul™ was resumed with a significant increase in dosage, seeking to exert control over the disease.

By July 2013, Isabel's results began to show an improvement that resulted in a reduction of the main lesion and in the non-appearance of new lesions. Her blood tests were normal.

By October 2013, a control CT scan was performed showing a lesion-free liver, decreased pulmonary involvement and stability in the abdominal lesion.

In January 2014, the results continued to be stable, the patient had no symptoms of the disease, so she continued to lead a normal life.

In June 2014, everything continued to be stable. At that time Isabel stopped receiving maintenance cycles of chemotherapy.

In control CT scans in August 2014 and January 2015, again the disease appeared stable, without any change. However, in January 2015, an increase in the tumor marker was

increase in the tumor marker, so the dose was increased. In cases where the disease is aggressive and is brought under control, it is normal for there to occasionally be an increase in activity seen in the antigen values. The response in these situations is to increase the dose, to try to control the process.

In the CT scan of June 2015, again it is observed that the disease has not progressed, that it remains the same and the antigen is controlled within normal values.

The results of the tumor marker have continued to vary, although the CT scans continue to show that the disease is controlled and that there is no increase in lesions or appearance of new tumors.

This means that the disease is still fighting its way through. The only way to maintain control is to continue with the Escozul™ treatment with progressive dose increases, seeking to maintain and improve the results obtained.

As we always explain to our patients, Escozul™ is not considered a cure for cancer, at this time we have managed to keep the disease under control and the patient can live a practically normal life with cancer.

It is important to point out that it is not possible to generalize any result with Escozul™ in order to avoid creating false expectations in people. Each case we receive is analyzed in order to inform the family what to expect. Each person is a completely different universe, even if they have the same disease. This document is not a testimony but a summary of evolution where medical information is available for consultation.

Medical Documents

Initial Diagnosis:

History of operated breast CA. Ovarian cancer (serous adenocarcinoma IIIC) with peritoneal carcinomatosis, pelvic tumor.

Indicators:

• - LDH=1821
• - CA125=675.51

Symptoms:

• - Abdominal pain
• - Loss of appetite
• - Constipation

Treatments received:

Started on Escozul™ in February 2015. Started in conjunction chemotherapy, to receive 6 cycles and subsequent evaluation for surgery.

Escozul™ is a natural product that has the ability to kill tumor cells without being a cure for cancer. Its ability to inhibit malignant cell growth allows it to be used as a disease controller and the work approach is done looking for the patient to be able to live with his disease with the least possible affectation to his daily routine.

Evolution and current results:

A progressive decrease in CA125 was observed, until it reached 20.40 in April 2015, so it was decided to reevaluate for surgery before the previously established time and surgery was performed in May. Uterus, ovary and parts of the peritoneum were removed.

The CA125 antigen continues to decrease, with a current value of 15.20.

The patient is well, in good physical condition, continues to consume Escozul™ with progressive doses in search of maintaining these results and continues with adjuvant chemotherapy post surgery.

Summary:

The results obtained in this case are important, by achieving with the joint application of Escozul™ and chemotherapy, faster and more effective results on the disease, which have allowed to remove the tumors by surgery, in a minimum time.

Medical Documents